Short Reads

Premium

Roche announced a $5.7 billion hostile takeover bid for Illumina. Under the terms of the proposed deal, Roche would acquire all outstanding Illumina shares for $44.50 each. Roche also announced its picks for Illumina's board of directors, should the deal go through. In response, Illumina's board of directors adopted a poison pill provision.

In a separate announcement, Illumina's board unanimously rejected Roche's offer, calling
it "grossly inadequate."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.